USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Deuruxolitinib
D11867 Deuruxolitinib phosphate (USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
DG01642 CYP2C9 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11867 Deuruxolitinib phosphate (USAN) <US>
JAK2
D11867 Deuruxolitinib phosphate (USAN) <US>
TYK2
D11867 Deuruxolitinib phosphate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11867
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11867
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11867
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG03114 Deuruxolitinib
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03114 Deuruxolitinib
DG01642 CYP2C9 substrate
DG03114 Deuruxolitinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03114 Deuruxolitinib